Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas.
Human endometrial cancer expresses both the known estrogen receptors (ER-alpha and ER-beta). The significance of the relative expression of both ER subtypes in endometrial adenocarcinomas remains to be clarified and the usefulness of the determination of the receptor status in endometrial cancer patients is still controversially discussed. Therefore, the aims of this study were the evaluation of the expression patterns of ER-alpha and ER-beta with the characterization of the prognostic significance in uterine endometrioid adenocarcinomas. Pathological and surgical records of 214 patients who were diagnosed with an endometrioid adenocarcinoma without other histological types (including mucinous, mixed, squamous or villoglandular differentiation) were reviewed for both estrogen receptors. The expression of both estrogen receptors was demonstrated in malignant endometrioid adenocarcinomas. ER-alpha was associated with histological differentiation, while ER-beta demonstrated an association with ovarial invasion. The loss of receptor positivity for ER-alpha resulted in a poorer cause-specific survival in endometrial cancer patients, while ER-beta did not affect survival. Interestingly, metastatic patients who expressed ER-alpha or ER-beta had a better survival outcome than estrogen receptor negative patients. Moreover, when tumor samples of affected patients expressed ER-alpha, they had a better cause-specific survival compared to negative findings regarding both estrogen receptors. However, ER-alpha and ER-beta were not independent factors with survival in endometrial adenocarcinoma patients. Therefore, the analysis of both estrogen receptors might be used as a marker to identify high-risk patients only in a subset of patients with endometrioid adenocarcinoma.
Mylonas
Ioannis
I
First Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Munich, D-80337 Munich, Germany. ioannis.mylonas@med.uni-muenchen.de
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018269:Carcinoma, Endometrioid / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000401:mortality; D047628:Estrogen Receptor alpha / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D047629:Estrogen Receptor beta / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta